1

2

3

4

5

## GLICLAZIDE SUSTAINED-RELEASE TABLETS

(GLICLAZIDUM COMPRESSI PROLONGATI)

# Draft proposal for inclusion in The International Pharmacopoeia

(30 June 2025)

6

## DRAFT FOR COMMENTS

Please submit your comments through the online platform, PleaseReview<sup>TM</sup> <a href="https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=341">https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=341</a>

If not registered or included in our mailing list, kindly submit your request with your full name, email address and organization/affiliation to nsp@who.int.

For any technical questions, you may contact **Dr Herbert Schmidt**, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (<a href="mailto:schmidth@who.int">schmidth@who.int</a>), with a copy to **Ms Sinéad Jones** (<a href="mailto:jonessi@who.int">jonessi@who.int</a>), msp@who.int).

Comments should be submitted through the online platform on or by **29 August 2025**. Please note that only comments received by this deadline will be considered for the preparation of this document.

Our working documents are sent out electronically and uploaded into PleaseReview<sup>TM</sup>. The working documents are also placed on the WHO Medicines website (<a href="https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/working-documents-public-consultation">https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/working-documents-public-consultation</a>) under the "Working documents in public consultation".

7 8 9

#### © World Health Organization 2025

10

All rights reserved.

11 12 13

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

15 16 17 Please send any request for permission to: Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: nsp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

30 31 32

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

### SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/25.975

## GLICLAZIDE SUSTAINED-RELEASE TABLETS

### (GLICLAZIDUM COMPRESSI PROLONGATI)

DescriptionDateFirst draft prepared.March 2025Discussion at the informal Consultation on Quality<br/>Control and Pharmacopoeial Specifications of MedicinesApril 2025Draft revision sent out for public consultationAugust – September<br/>2025Draft revision presented at the 59th meeting of the Expert<br/>Committee on Specifications for Pharmaceutical<br/>PreparationsOctober 2025Further follow-up action as required.Further follow-up action as required.

38

34

35

36

37

39

- 40 [Note from the Secretariat. The monograph on Gliclazide sustained-release tablets is
- 41 proposed for inclusion in The International Pharmacopoeia.
- 42 The monograph is based on information found in other pharmacopoeias, in the
- 43 scientific literature and on laboratory investigations.
- 44 Draft monographs are subject to change.]

45

46

# GLICLAZIDE SUSTAINED-RELEASE TABLETS 47 (GLICLAZIDUM COMPRESSI PROLONGATI) 48 49 Category. Antidiabetic drug. 50 **Storage.** Gliclazide sustained-release tablets should be kept in a well-closed container. 51 52 Additional information. Strengths in the current WHO Model List of Essential Medicines (EML): 30 mg, 60 mg and 80 mg sustained -release tablets. 53 **Requirements** 54 Comply with the monograph for *Tablets*. 55 **Definition.** Gliclazide sustained-release tablets contain not less than 90.0% and not 56 more than 110.0% of the labelled amount of Gliclazide (C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S). They are 57 formulated so that the active ingredient is released over a period of several hours. 58 Production. A suitable dissolution test is carried out to demonstrate the appropriate 59 release of Gliclazide. The dissolution profile reflects the in vivo performance which in 60 turn is compatible with the dosage schedule recommended by the manufacturer. 61 **Identity tests** 62 Either test A alone, or any two of tests B, C or D may be applied. 63 Shake a quantity of the powdered tablets equivalent to 0.12 g of Gliclazide with A. 64 20 mL of dichloromethane R, centrifuge, filter and evaporate the filtrate to 65 dryness. Carry out the examination as described under 1.7 Spectrophotometry in 66

the infrared region. The infrared absorption spectrum is concordant with the

67

<sup>&</sup>lt;sup>1</sup> A 0.45 μm PTFE membrane syringe filter was found suitable.

- spectrum obtained from gliclazide RS treated similarly.
- 69 B. Carry out the test as described under <u>1.14.1 Chromatography</u>, High-performance
- 70 liquid chromatography, using the conditions and solutions given under "Assay".
- 71 The retention time of the principal peak in the chromatogram obtained with
- solution (1) corresponds to the retention time of the peak due to gliclazide in the
- chromatogram obtained with solution (2).
- 74 C. The absorption spectrum (<u>1.6 Spectrophotometry in the visible and ultraviolet</u>
- 75 <u>regions</u>) of a 0.01 mg per mL solution of the test substance prepared in a mixture
- of 45 volumes of acetonitrile R and 55 volumes of water R, when observed
- between 200 nm and 300 nm, exhibits minimum at about 213 nm and a maximum
- 78 at about 229 nm.
- Alternatively, and in combination with identity test B, where a diode-array
- detector is available, record the UV spectrum of the principal peak in the
- chromatograms with a diode array detector in the range of 210 nm to 400 nm.
- The UV spectrum of the principal peak in the chromatogram obtained with
- solution (1) corresponds to the UV spectrum of the peak due to gliclazide in the
- chromatogram obtained with solution (2).
- 85 D. Carry out the test as described under <u>1.14.1 Chromatography</u>, Thin-layer
- chromatography, using silica gel R6 as the coating substance and a freshly
- prepared mixture of toluene R and ethyl acetate R (1:1 V/V) as the mobile phase.
- Apply separately to the plate 2 µL of each of the following 2 solutions. For
- solution (A), transfer a quantity of the powdered tablets, nominally containing
- 90 10 mg of gliclazide, to a 25 mL flask and add 15 mL of dichloromethane R.
- Stopper the flask and sonicate for 15 minutes. Make up to volume, filter the
- 92 suspension and use the clear supernatant. For solution (B), use a solution
- containing 0.4 mg of gliclazide RS per mL.
- Develop the plate. After removing the plate from the chromatographic chamber

allow it to dry in air or in a current of air. Allow the plate to cool and examine 95 the chromatogram in daylight and under ultraviolet light (254 and 360 nm). 96 The principal spot in the chromatogram obtained with solution (A) corresponds 97 in position, appearance and intensity with the spot due to gliclazide in the 98 chromatogram obtained with solution (B). 99 100 **Related substances**. Prepare the solutions immediately before use. Carry out the test as described under 1.14.1 Chromatography, High-pressure liquid chromatography, 101 using a stainless steel column (4 mm x 25 cm) packed with particles of silica gel, 102 the surface of which has been modified with chemically-bonded octylsilyl groups<sup>2</sup> 103 104  $(4 \mu m)$ . As the mobile phase, use a mixture of 0.1 volume of triethylamine R, 0.1 volume of 105 trifluoroacetic acid R, 40 volumes of acetonitrile R and 60 volumes of water R. 106 Operate with a flow rate of 0.9 mL per minute. As a detector, use an ultraviolet 107 spectrophotometer set at a wavelength of 235 nm. Maintain the autosampler 108 temperature at 4 °C. 109 Prepare the following solutions. Use as a diluent a mixture of 45 volumes of 110 acetonitrile R and 55 volumes of water R. 111 For solution (1), shake a quantity of the powdered tablets, nominally containing 112 40.0 mg of gliclazide for about an hour with 90 mL of acetonitrile R. Dilute to 200.0 113 mL with water R, filter<sup>3</sup> and use the filtrate. 114 For solution (2), dilute 1.0 mL of solution (1) to 200.0 mL with the diluent. 115

<sup>&</sup>lt;sup>2</sup> A Superspher 60 RP-8 LiChroCART column has been found suitable.

<sup>&</sup>lt;sup>3</sup> A 0.45 µm PTFE membrane syringe filter was found suitable.

- For solution (3), dissolve 8 mg of gliclazide impurity F RS in 100.0 mL of the
- diluent. Dilute 0.5 mL of this solution to 100.0 mL with the diluent.
- For solution (4), dissolve 5 mg of the test substance, 5 mg of gliclazide impurity A
- and 15 mg of gliclazide impurity F RS in 23 mL of acetonitrile R and dilute to 50.0
- mL with water R. Dilute 1 mL of the solution to the 100 mL with the diluent.
- For solution (5), dilute 10.0 mL of solution (2) to 50.0 mL with the diluent.
- Inject 100 μL each of solutions (1), (2) (3), (4) and (5). Record the chromatogram
- for about 2 times the retention time of gliclazide (retention time about 16 minutes).
- Use the chromatogram obtained with solution (4) to identify the peaks due to
- gliclazide and gliclazide impurities A and F.
- The impurities are eluted, if present, at the following relative retentions with
- reference to gliclazide: impurity A about 0.3; impurity F about 0.9.
- The test is not valid unless, in the chromatogram obtained with solution (4), the
- resolution between gliclazide impurity F and gliclazide is at least 1.5 and the resolution
- between gliclazide impurity A and the preceding negative system peak is at least 1.5.
- Also, the test is not valid unless in the chromatogram obtained with solution (5) the
- peak due to gliclazide is detected with a signal-to-noise ratio of at least 10.
- 133 In the chromatogram obtained with solution (1):
- the area of any peak corresponding to impurity A is not greater than the area
- of the peak due to gliclazide in the chromatogram obtained with solution (2)
- 136 (0.5 %);
- the area of any peak corresponding to impurity F is not greater than the area
- of the peak due to gliclazide impurity F in the chromatogram obtained with
- solution (3) (0.2 %);

- the area of any other impurity peak is not greater than 0.4 times the peak due to gliclazide in the chromatogram obtained with solution (2) (0.2 %).
- The sum of the areas of all impurity peaks is not greater than 1.0 %. Disregard any peaks with an area of less than the area of the peak due to gliclazide in the chromatogram obtained with solution (5) (0.10 %).
- 145 Assay. Carry out the test as described under 1.14.1 Chromatography, Liquid
- chromatography, using the conditions given under "Related substances", with the
- 147 following modifications.
- Prepare the following solutions. Use as a diluent a mixture of 45 volumes of acetonitrile
- R and 55 volumes of water R.
- For solution (1), weigh and powder 20 tablets. Shake a quantity of the powdered tablets,
- nominally containing 40.0 mg of the test substance, for about an hour with 90 mL of
- acetonitrile R. Dilute to 200.0 mL with water R, filter<sup>3</sup> and use the filtrate.
- For solution (2), dissolve 40.0 mg of gliclazide RS in 200.0 mL of diluent.
- 154 Inject 50 μL each of solutions (1) and (2).
- 155 Measure the areas of the peaks corresponding to gliclazide obtained in the
- chromatograms of solutions (1) and (2) and calculate the percentage content of
- Gliclazide ( $C_{15}H_{21}N_3O_3S$ ) in the tablets, using the declared content of  $C_{15}H_{21}N_3O_3S$  in
- 158 gliclazide RS.

159

#### **Impurities**

- The impurities limited by the requirements of this monograph include A, C, D, E, F and
- 161 G listed in the monograph on Gliclazide.

162 \*\*\*